Bolger G T, Weissman B A, Skolnick P
Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):373-7. doi: 10.1007/BF00692903.
Mice injected with the calcium agonist BAY K 8644 (2-4 mg/kg, i.p.) displayed profound behavioral changes including ataxia, decreased motor activity, Straub tail, arched back, limb clonus and tonus, and an increased sensitivity to auditory stimulation. BAY K 8644 significantly impaired rotorod performance in mice with an ED50 of 0.8 mg/kg. The behavioral effects of BAY K 8644 were antagonized by nifedipine, but not by the non-dihydropyridine calcium channel antagonist verapamil or the alpha-adrenoceptor antagonist prazosin. Further, the actions of BAY K 8644 were not mimicked by the alpha-adrenoceptor agonist methoxamine at doses up to 4.5 mg/kg. These observations, coupled with the findings that BAY K 8644 is a potent, competitive inhibitor of [3H]nitrendipine binding to the dihydropyridine binding site in mouse brain (Ki = 7.0 X 10(-9) M), suggests that BAY K 8644 may produce its behavioral actions via an interaction with the DHP binding site, which has been linked to the control of calcium flux across membranes in peripheral tissues.
注射钙激动剂BAY K 8644(2 - 4毫克/千克,腹腔注射)的小鼠表现出深刻的行为变化,包括共济失调、运动活动减少、斯特劳布尾、弓背、肢体阵挛和紧张度增加,以及对听觉刺激的敏感性增加。BAY K 8644显著损害小鼠的转棒试验性能,半数有效剂量(ED50)为0.8毫克/千克。硝苯地平可拮抗BAY K 8644的行为效应,但非二氢吡啶类钙通道拮抗剂维拉帕米或α - 肾上腺素能受体拮抗剂哌唑嗪则不能。此外,高达4.5毫克/千克剂量的α - 肾上腺素能受体激动剂甲氧明不能模拟BAY K 8644的作用。这些观察结果,再加上BAY K 8644是[3H]尼群地平与小鼠脑二氢吡啶结合位点结合的强效竞争性抑制剂(抑制常数Ki = 7.0×10⁻⁹ M)这一发现,表明BAY K 8644可能通过与二氢吡啶结合位点相互作用产生其行为效应,该位点与外周组织中跨膜钙通量的控制有关。